AnaptysBio, Inc. reported earnings results for the fourth quarter ended December 31, 2022. For the fourth quarter, the company reported net loss was USD 26.41 million compared to USD 32.54 million a year ago. Basic loss per share from continuing operations was USD 0.93 compared to USD 1.18 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.77 USD | -1.98% |
|
+1.45% | +10.97% |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.97% | 649M | |
+18.15% | 124B | |
+18.02% | 112B | |
+3.61% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-16.66% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- AnaptysBio, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022